Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer.
BACKGROUND
Our purpose is to examine the relationship of Health related quality of life measured by EORTC QLQc30, QLQ-LC13; FACT-L, LCSS, Eq5D) with survival in advanced lung cancer patients. A total of 299 Lung Cancer (LC) patients were, included in this national multicenter Project entitled of "the LC Quality of Life Project (AKAYAK). Baseline scores were analyzed by using Cox's proportional hazard regression to identify factors that influenced survival. Univariate and multivariate models were run for each of the scales included in the study.


RESULTS
Mean and median survival were 12.5 and 8.0 months respectively. Clinical stage (as TNM), comorbidity; symptom scales of fatigue, insomnia, appetit loss and constipation were associated with survival after adjustment for age and sex. Global, physical and role functioning scales of QLQc30; physical and functional scales of LCS and TOI of the FACT-L was also associated with survival. Mobility and Usual activities dimensions of the Eq5D; Physical functioning and the constipation symptom scale of the QLQ-c30; and LCS and TOI scores of the FACT-L remained statistically significant after adjustment. LC13 and LCSS scales were not predictors of survival.


CONCLUSIONS
HRQOL serves as an additional predictive factor for survival that supplements traditional clinical factors. Besides the strong predictive ability of ECOG on survival, FACT-L and the Eq5D are the most promising HRQOL instruments for this purpose.
Institute of Public Health, Hacettepe University, Ankara, Turkey.
Sultan
S
Eser
Department of Chest Diseases, Faculty of Medicine, Ege University, İzmir, Turkey.
Tuncay
T
Göksel
Dr. Suat Seren Chest Diseases and Thoracic Surgery Education and Research Hospital, İzmir, Turkey.
Ahmet Emin
AE
Erbaycu
Department of Social Work, Faculty of Health Sciences, Celal Bayar University, Manisa, Turkey.
Hakan
H
Baydur
Department of Chest Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Burcu
B
Başarık
Department of Chest Diseases, Nevsehir State Hospital, Nevsehir, Turkey.
Ayşen Öz
AÖ
Yanık
Dr. Suat Seren Chest Diseases and Thoracic Surgery Education and Research Hospital, İzmir, Turkey.
Kader Kıyar
KK
Gürsul
Department of Chest Diseases, School of Medicine, Ege University, İzmir, Turkey.
Pınar
P
Çelik
Department of Chest Diseases, School of Medicine, Trakya University, Edirne, Turkey.
Ebru Çakır
EÇ
Ediz
Department of Chest Diseases, School of Medicine, Trakya University, Edirne, Turkey.
Osman
O
Hatipoğlu
Department of Chest Diseases, School of Medicine, Pamukkale University, Denizli, Turkey.
Bedriye Atay
BA
Yayla
Department of Chest Diseases, School of Medicine, Pamukkale University, Denizli, Turkey.
Sevin
S
Başer
Department of Public Health (Halk Sağlığı AD), School of Medicine (Tıp Fak), Celal Bayar University, 45040 Manisa, Turkey.
Erhan
E
Eser
HRQOL; Lung cancer; Prognostic factors; Survival